This site uses cookies to improve your experience. To help us insure we adhere to various privacy regulations, please select your country/region of residence. If you do not select a country, we will assume you are from the United States. Select your Cookie Settings or view our Privacy Policy and Terms of Use.
Cookie Settings
Cookies and similar technologies are used on this website for proper function of the website, for tracking performance analytics and for marketing purposes. We and some of our third-party providers may use cookie data for various purposes. Please review the cookie settings below and choose your preference.
Used for the proper function of the website
Used for monitoring website traffic and interactions
Cookie Settings
Cookies and similar technologies are used on this website for proper function of the website, for tracking performance analytics and for marketing purposes. We and some of our third-party providers may use cookie data for various purposes. Please review the cookie settings below and choose your preference.
Strictly Necessary: Used for the proper function of the website
Performance/Analytics: Used for monitoring website traffic and interactions
The results support the use of workflows to reduce radiation exposure during catheter ablation for the treatment of paroxysmal atrial fibrillation (AFib) while maintaining safety, efficacy, and long-term patient outcomes comparable to traditional procedures.1 1 These included one pseudoaneurysm, one PV stenosis and one hematoma.1
CardioSignal has already developed digital biomarkers for AFib and heart failure, while more solutions could be on the way for aortic stenosis, coronary artery disease, and pulmonary artery hypertension.
The VARIPULSE Platform is designed to enable pulmonary vein isolation with the versatility of a catheter loop, a simple generator user interface, and a mapping system that provides an intuitive, reproducible workflow with real-time visualization, contact indicator, and PF tagging mechanisms. In the U.S.,
Image courtesy: Getty Images christine.book Sat, 05/18/2024 - 14:26 May 18, 2024 — The Heart Rhythm Society ( HRS ) has announced the findings of three new studies demonstrating the safety and efficacy of pulsed field ablation (PFA), a nonthermal ablation treatment for patients with atrial fibrillation ( AFib ).
The pipeline of algorithms likely to clear regulatory hurdles and enter the cardiac market over the next 12-18 months include those for Pulmonary Hypertension, Cardiac Amyloidosis, Diastolic dysfunction, and Hyperkalaemia. Fertile Partnerships Ongoing research partnerships have driven much of recent developments seen in the market.
New science presented at AHA 2024 and simultaneously published in JACC: Advances provide insights on emerging topics such as the use of artificial intelligence (AI)-enabled left atrial (LA) volumetry in coronary artery calcium (CAC) scans to predict atrial fibrillation (AFib); the role of treating hospitals in facilitating cardiac rehabilitation (CR); (..)
We organize all of the trending information in your field so you don't have to. Join thousands of users and stay up to date on the latest articles your peers are reading.
You know about us, now we want to get to know you!
Let's personalize your content
Let's get even more personalized
We recognize your account from another site in our network, please click 'Send Email' below to continue with verifying your account and setting a password.
Let's personalize your content